- Dyno to receive upfront and is eligible to receive ~$1.8B milestones including development and commercial milestones along with royalties on any product emerges during the collaboration
- Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy while Roche and Spark will conduct preclinical, clinical, and commercialization activities for the products using the novel capsids
- The collaboration leverages Dyno’s CapsidMap platform for the development of next-generation AAV vectors for CNS diseases and liver-directed therapies for the portfolio of both Roche and Spark
Click here to read the full press release/ article | Ref: Dyno Therapeutics | Image: Oncology Nurse Advisor
The post Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~.8B first appeared on PharmaShots.